Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: Effect of Nitecapone (cas 116313-94-1)
-
Add time:08/09/2019 Source:sciencedirect.com
1. A gastric mucosal laminin receptor has been isolated from the epithelial cell membrane by affinity chromatography on Sepharose-bound laminin, and following radioiodination was incorporated into liposomes which displayed specific affinity towards the laminin-coated surface.2. The binding of liposomal receptor to the laminin-coated surface was inhibited by Helicobacter pylori lipopolysaccharide and reached a maximum value of 96% at 50 μg/ml.3. The inhibitory effect of H. pylori lipopolysaccharide on the receptor-laminin binding was prevented by an antiulcer agent, nitecapone. The effect was concentration dependent and produced a maximum response of 83% at 30 μg/ml of drug concentration.4. The results demonstrate that H. pylori is capable of disrupting gastric mucosal integrity by interfering with epithelial cell-laminin binding, and that an antiulcer agent, nitecapone, counteracts this effect.
We also recommend Trading Suppliers and Manufacturers of Nitecapone (cas 116313-94-1). Pls Click Website Link as below: cas 116313-94-1 suppliers
Prev:Determination of a catechol-O-methyltransferase inhibitor, Nitecapone (cas 116313-94-1), in human plasma and urine by liquid chromatography
Next:[54] Antioxidant activity of Nitecapone (cas 116313-94-1) and its analog OR-1246: Effect of structural modification on antioxidant action) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pain Behavior and Response Properties of Spinal Dorsal Horn Neurons Following Experimental Diabetic Neuropathy in the Rat: Modulation by Nitecapone (cas 116313-94-1), a COMT Inhibitor with Antioxidant Properties08/11/2019
- [54] Antioxidant activity of Nitecapone (cas 116313-94-1) and its analog OR-1246: Effect of structural modification on antioxidant action08/10/2019
- Determination of a catechol-O-methyltransferase inhibitor, Nitecapone (cas 116313-94-1), in human plasma and urine by liquid chromatography08/08/2019
- Protection against alcohol-induced gastric mucosal injury by Nitecapone (cas 116313-94-1)08/07/2019
- Nitecapone (cas 116313-94-1) as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting08/06/2019
- Nitecapone (cas 116313-94-1) effect on the synthesis and secretion of gastric sulfomucin08/05/2019
- Role of ascorbate in protection by Nitecapone (cas 116313-94-1) against cardiac ischemia-reperfusion injury08/04/2019
- Antioxidant properties of Nitecapone (cas 116313-94-1) (OR-462)08/03/2019
- Nitecapone (cas 116313-94-1) reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats08/02/2019